A prominent, safe and efficient therapy for patients with chronic myeloid leukemia (CML) is inhibiting oncogenic protein BCR::ABL1 in a targeted manner with imatinib, a tyrosine kinase inhibitor. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.